Extravasation of an antibody-drug conjugate: A case report of epidermal necrosis after trastuzumab-emtansine extravasation

Bastiaan T G M Sallevelt; Teun Teunis; Mariette J Agterof; Marcel P H van den Broek

doi:10.1111/jcpt.13148

Extravasation of an antibody-drug conjugate: A case report of epidermal necrosis after trastuzumab-emtansine extravasation

Bastiaan T G M Sallevelt, Teun Teunis, Mariette J Agterof, Marcel P H van den Broek

Research output: Contribution to journal › Article › Academic › peer-review

9 Downloads (Pure)

Abstract

WHAT IS KNOWN AND OBJECTIVE: Trastuzumab-emtansine is an antibody-drug conjugate developed to decrease off-target toxicity. According to the product label, reactions secondary to extravasation are mild or moderate.

CASE SUMMARY: We report on a 51-year-old woman who developed epidermal necrosis after extravasation of trastuzumab-emtansine, which required surgical intervention. Six weeks later, the lesions were healed with residual hyperpigmentation.

WHAT IS NEW AND CONCLUSION: We describe the course of a case of severe toxicity following trastuzumab-emtansine extravasation. We provide treatment recommendations and recommend amending the information on the product label on extravasation.

Original language	English
Pages (from-to)	832-835
Number of pages	4
Journal	Journal of Clinical Pharmacy and Therapeutics
Volume	45
Issue number	4
DOIs	https://doi.org/10.1111/jcpt.13148
Publication status	Published - Aug 2020

Keywords

antibody-drug conjugate
chemotherapy
epidermal necrosis
extravasation
oncology
trastuzumab-emtansine

Access to Document

10.1111/jcpt.13148

jcpt.13148Final published version, 525 KB

Cite this

@article{5846c6511ab8422699f678e26552c155,

title = "Extravasation of an antibody-drug conjugate: A case report of epidermal necrosis after trastuzumab-emtansine extravasation",

abstract = "WHAT IS KNOWN AND OBJECTIVE: Trastuzumab-emtansine is an antibody-drug conjugate developed to decrease off-target toxicity. According to the product label, reactions secondary to extravasation are mild or moderate.CASE SUMMARY: We report on a 51-year-old woman who developed epidermal necrosis after extravasation of trastuzumab-emtansine, which required surgical intervention. Six weeks later, the lesions were healed with residual hyperpigmentation.WHAT IS NEW AND CONCLUSION: We describe the course of a case of severe toxicity following trastuzumab-emtansine extravasation. We provide treatment recommendations and recommend amending the information on the product label on extravasation.",

keywords = "antibody-drug conjugate, chemotherapy, epidermal necrosis, extravasation, oncology, trastuzumab-emtansine",

author = "Sallevelt, {Bastiaan T G M} and Teun Teunis and Agterof, {Mariette J} and {van den Broek}, {Marcel P H}",

note = "Publisher Copyright: {\textcopyright} 2020 The Authors. Journal of Clinical Pharmacy and Therapeutics published by John Wiley & Sons Ltd",

year = "2020",

month = aug,

doi = "10.1111/jcpt.13148",

language = "English",

volume = "45",

pages = "832--835",

journal = "Journal of Clinical Pharmacy and Therapeutics",

issn = "0269-4727",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Extravasation of an antibody-drug conjugate

T2 - A case report of epidermal necrosis after trastuzumab-emtansine extravasation

AU - Sallevelt, Bastiaan T G M

AU - Teunis, Teun

AU - Agterof, Mariette J

AU - van den Broek, Marcel P H

PY - 2020/8

Y1 - 2020/8

N2 - WHAT IS KNOWN AND OBJECTIVE: Trastuzumab-emtansine is an antibody-drug conjugate developed to decrease off-target toxicity. According to the product label, reactions secondary to extravasation are mild or moderate.CASE SUMMARY: We report on a 51-year-old woman who developed epidermal necrosis after extravasation of trastuzumab-emtansine, which required surgical intervention. Six weeks later, the lesions were healed with residual hyperpigmentation.WHAT IS NEW AND CONCLUSION: We describe the course of a case of severe toxicity following trastuzumab-emtansine extravasation. We provide treatment recommendations and recommend amending the information on the product label on extravasation.

AB - WHAT IS KNOWN AND OBJECTIVE: Trastuzumab-emtansine is an antibody-drug conjugate developed to decrease off-target toxicity. According to the product label, reactions secondary to extravasation are mild or moderate.CASE SUMMARY: We report on a 51-year-old woman who developed epidermal necrosis after extravasation of trastuzumab-emtansine, which required surgical intervention. Six weeks later, the lesions were healed with residual hyperpigmentation.WHAT IS NEW AND CONCLUSION: We describe the course of a case of severe toxicity following trastuzumab-emtansine extravasation. We provide treatment recommendations and recommend amending the information on the product label on extravasation.

KW - antibody-drug conjugate

KW - chemotherapy

KW - epidermal necrosis

KW - extravasation

KW - oncology

KW - trastuzumab-emtansine

U2 - 10.1111/jcpt.13148

DO - 10.1111/jcpt.13148

M3 - Article

C2 - 32412114

SN - 0269-4727

VL - 45

SP - 832

EP - 835

JO - Journal of Clinical Pharmacy and Therapeutics

JF - Journal of Clinical Pharmacy and Therapeutics

IS - 4

ER -

Extravasation of an antibody-drug conjugate: A case report of epidermal necrosis after trastuzumab-emtansine extravasation

Abstract

Keywords

Access to Document

Fingerprint

Cite this